Phospho-MAPK14 (Tyr182) Antibody

What is MAPK14 and why is its phosphorylation important?

MAPK14 (Mitogen-activated protein kinase 14), also known as p38α, is a key protein kinase involved in cellular stress responses, inflammation, and signal transduction. The protein has multiple alternative names including CSBP, CSBP1, CSBP2, CSPB1, MXI2, and SAPK2A . Phosphorylation of MAPK14 at Thr180 and Tyr182 is essential for its activation and subsequent involvement in downstream signaling cascades. This dual phosphorylation serves as a critical regulatory mechanism, enabling MAPK14 to phosphorylate its substrates and influence various cellular processes including inflammation, apoptosis, cell cycle regulation, and stress responses .

How do I select the appropriate phospho-MAPK14 antibody for my research?

When selecting a phospho-MAPK14 antibody, consider the following methodological approach:

• Determine which application(s) you need (Western blot, immunohistochemistry, etc.)

• Verify species reactivity matches your experimental model

• Check if the antibody is phospho-specific (most commercial antibodies target both T180 and Y182)

• Review validation data from manufacturers, including specificity tests

• Assess literature citations to evaluate real-world performance

For example, the Abcam antibody (ab308038) is suitable for Western blot and IHC-P applications with human samples, while the R&D Systems antibody (MAB8691) has been validated for Western blot applications with human samples .

What controls should I include when using phospho-MAPK14 antibodies?

For rigorous experimental design when using phospho-MAPK14 antibodies, include the following controls:

• Positive control: Cells treated with known MAPK14 activators (e.g., anisomycin, UV irradiation)

• Negative control: Untreated cells or samples treated with MAPK14 inhibitors

• Phospho-peptide competition: Preincubation of antibody with phosphopeptide to confirm specificity

• Total MAPK14 antibody: Run in parallel to distinguish between changes in phosphorylation versus total protein expression

For example, HeLa cells treated with anisomycin (5 μg/mL for 30 min) provide a reliable positive control, as demonstrated in validation experiments for the Abcam antibody . Competition with a phosphopeptide can confirm antibody specificity, as shown in lane 2 of the Western blot validation data .

How can phospho-MAPK14 antibodies be used to investigate drug mechanisms of action?

Phospho-MAPK14 antibodies can be instrumental in dissecting drug mechanisms of action through a multi-step approach:

• Baseline phosphorylation assessment: Measure p-MAPK14 (T180/Y182) levels before drug treatment

• Time-course analysis: Monitor changes in phosphorylation after drug administration at various timepoints

• Dose-response studies: Determine relationship between drug concentration and p-MAPK14 levels

• Protein complex analysis: Investigate drug effects on MAPK14 interactome using co-immunoprecipitation

• Downstream target analysis: Assess phosphorylation status of MAPK14 substrates

Research has demonstrated that different MAPK14 inhibitors (JX-401, sorafenib, and skepinone-L) uniquely perturb the MAPK14 signaling network. For example, both sorafenib and skepinone-L induce hyperphosphorylation of MAPK14 at Tyr182, while an N-terminal phosphorylation site (Ser2) remains unaltered . Interestingly, these inhibitors differently affect protein-protein interactions, with sorafenib uniquely reducing the binding of RPS6KA4 (MSK1) and PTPN7 to MAPK14 .

What are the challenges in detecting phospho-MAPK14 in clinical samples and how can they be overcome?

Detecting phospho-MAPK14 in clinical samples presents several challenges that can be methodologically addressed:

• Phosphorylation lability: Process samples immediately or use phosphatase inhibitors

• Low abundance: Employ signal amplification methods or more sensitive detection systems

• Background interference: Optimize blocking conditions and antibody dilutions

• Tissue heterogeneity: Use laser capture microdissection for specific cell populations

• Validation across techniques: Confirm findings using multiple methods (IHC, Western blot)

For IHC applications, antigen retrieval is critical. As demonstrated with the Abcam antibody, optimal results were achieved using 10mM sodium citrate (pH 6.0) with microwave heating for 8-15 minutes, followed by blocking in 3% H₂O₂-methanol for 15 minutes at room temperature .

How can I investigate the relationship between MAPK14 phosphorylation and its downstream effectors?

To investigate the relationship between MAPK14 phosphorylation and its downstream effectors, implement this systematic approach:

• Phosphorylation time-course: Monitor p-MAPK14 levels after stimulus application

• Inhibitor studies: Use MAPK14-specific inhibitors to block signaling

• Knockdown/knockout experiments: Reduce MAPK14 expression using siRNA or CRISPR

• Protein interaction analysis: Identify binding partners using co-immunoprecipitation

• Phosphoproteomic profiling: Assess global phosphorylation changes in response to MAPK14 activation/inhibition

Research demonstrates that knockdown of MAPK14 using siRNA decreases p-MAPK14 protein levels and reduces clonal formation, proliferation, and migration abilities of bladder cancer cells . Furthermore, p-MAPK14 has been shown to interact with RUNX2, maintaining its protein stability without affecting its mRNA levels .

What is the role of phospho-MAPK14 in cancer progression and how can it be studied?

Phospho-MAPK14 plays significant roles in cancer progression that can be studied through these methodological approaches:

• Expression analysis: Compare p-MAPK14 levels between normal and tumor tissues

• Correlation studies: Assess relationship between p-MAPK14 expression and clinical outcomes

• Functional assays: Measure effects of MAPK14 inhibition on cancer cell behaviors

• Mechanistic studies: Identify p-MAPK14-regulated genes and proteins in cancer cells

• In vivo models: Test effects of targeting p-MAPK14 on tumor growth and metastasis

Research has shown that p-MAPK14 (Thr180/Tyr182) is highly expressed in bladder cancer tissues and cell lines . Functional studies indicate that p-MAPK14 promotes bladder cancer cell proliferation and migration through interaction with RUNX2, suggesting p-MAPK14 could be a potential therapeutic target .

How can phospho-MAPK14 antibodies be used in multi-parameter analysis of signaling pathways?

For multi-parameter analysis of signaling pathways using phospho-MAPK14 antibodies, implement this comprehensive approach:

• Multiplex immunoassays: Simultaneously detect multiple phosphoproteins

• Sequential immunoblotting: Strip and reprobe membranes for different signaling proteins

• Immunofluorescence co-localization: Visualize spatial relationships between p-MAPK14 and other proteins

• Flow cytometry: Quantify phosphorylation at single-cell resolution

• Mass spectrometry: Identify phosphorylation sites and protein complexes

The MIP-APMS (Modifications, Interactions and Phenotypes by Affinity Purification Mass Spectrometry) approach exemplifies this type of analysis, enabling simultaneous identification of post-translational modifications and protein-protein interactions . This method revealed that MAPK14 inhibitors not only affect MAPK14 phosphorylation and interactions but also influence other signaling complexes, such as MAP3K7 .

How should I optimize Western blot protocols for phospho-MAPK14 detection?

To optimize Western blot protocols for phospho-MAPK14 detection, follow these methodological recommendations:

• Sample preparation: Include phosphatase inhibitors in lysis buffers

• Protein loading: Use 20-50 μg of total protein per lane

• Gel percentage: 10-12% SDS-PAGE gels provide optimal resolution

• Transfer conditions: Use PVDF membranes for better protein retention

• Blocking: 3-5% BSA (not milk) in TBS-T is preferable as milk contains phosphoproteins

• Antibody dilution: Optimize based on manufacturer recommendations (typically 1:1000-1:2000)

• Incubation: Overnight at 4°C for primary antibodies

For example, the R&D Systems protocol demonstrated successful detection of phospho-p38α (T180/Y182) at approximately 45 kDa in HeLa cells treated with UV light using 1 μg/mL of antibody concentration under reducing conditions with Immunoblot Buffer Group 1 .

What are the common sources of variability in phospho-MAPK14 immunodetection and how can they be minimized?

Common sources of variability in phospho-MAPK14 immunodetection and their solutions include:

• Sample handling: Standardize collection, processing, and storage protocols

• Phosphatase activity: Use fresh phosphatase inhibitor cocktails in all buffers

• Antibody quality: Purchase from reputable vendors and validate lot-to-lot consistency

• Experimental conditions: Control temperature, time, and reagent concentrations precisely

• Cell culture conditions: Standardize passage number, confluence, and serum starvation protocols

• Technical replication: Perform at least three independent experiments

• Quantification methods: Use appropriate software and normalization controls

When comparing results across experiments, normalize phospho-MAPK14 signals to total MAPK14 to account for variations in total protein expression. Including treatment controls (e.g., anisomycin-treated samples) in each experiment provides a reference point for signal intensity .

How can I distinguish between specific and non-specific signals when using phospho-MAPK14 antibodies?

To distinguish between specific and non-specific signals when using phospho-MAPK14 antibodies, employ these methodological approaches:

• Phosphopeptide competition: Pre-incubate antibody with phosphopeptide to block specific binding

• Dephosphorylation controls: Treat samples with lambda phosphatase before immunodetection

• Knockdown validation: Compare signals in MAPK14 knockdown/knockout cells

• Multiple antibodies: Use antibodies from different sources targeting the same epitope

• Signal abolishment: Verify signal disappearance after treatment with MAPK14 inhibitors

• Band size verification: Confirm signal appears at expected molecular weight (~38-45 kDa)

As demonstrated in the Abcam validation data, competition with phosphopeptide effectively abolishes the specific signal in anisomycin-treated HeLa cells, confirming antibody specificity . Additionally, proper controls such as secondary antibody-only samples help identify potential sources of background signal .

How can phospho-MAPK14 antibodies be integrated into single-cell analysis workflows?

Integration of phospho-MAPK14 antibodies into single-cell analysis requires these methodological considerations:

• Cell fixation/permeabilization: Optimize to maintain epitope accessibility

• Antibody validation: Verify specificity at single-cell level

• Multiplexing: Combine with other markers for comprehensive signaling analysis

• Analysis algorithms: Develop computational methods to interpret heterogeneous responses

• Spatial considerations: Integrate with imaging to maintain spatial context

Single-cell phospho-protein analysis can reveal the heterogeneity of MAPK14 activation within populations that might be masked in bulk analyses. This approach is particularly valuable in understanding differential responses to treatments and identifying resistant subpopulations in cancer research.

What are the latest approaches for studying temporal dynamics of MAPK14 phosphorylation?

Contemporary approaches for studying temporal dynamics of MAPK14 phosphorylation include:

• Live-cell imaging: Use fluorescent biosensors for real-time monitoring

• Microfluidic systems: Apply precisely timed stimuli and capture rapid responses

• High-throughput kinetic assays: Sample at multiple timepoints after stimulus

• Computational modeling: Integrate data into mathematical models of signaling kinetics

• Correlative microscopy: Combine live-cell observation with fixed-cell immunostaining

Time-resolved analysis of protein modifications and interactions, as demonstrated in the MIP-APMS approach, can reveal the dynamic assembly of protein communities in response to stimuli . This method has identified more than 50 previously undescribed post-translational modifications and hundreds of protein-protein interactions in immune protein complexes .